(Bloomberg) -- Novo Nordisk A/S has a successor waiting in the wings for the generation of weight-loss shots it pioneered: a pill that helps people shed pounds without the drawbacks of an injection.

Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition ...

Novo Nordisk on Tuesday reported that its new obesity pill that targets the amylin hormone led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation ...

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market. The company announced the completion of two ...

Novo Nordisk has had a setback in its quest to develop an insulin pill, CEO Lars Rebien Sorensen has revealed, saying the drug would be too expensive for payers to stomach in its current form.

Drug-coated balloon (DCB) angioplasty as the initial strategy for de novo coronary artery stenoses didn't measure up to ...

COPENHAGEN (Reuters) -Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to ...

Pharmaceutical giant Novo Nordisk (NVO) stock falls on Friday after receiving mixed data on its new oral weight-loss pill — the cannabinoid receptor Monlunabant — and is ramping up the ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

COPENHAGEN, Sept 11 (Reuters) - Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side ...